NewLink Genetics Corp. (NLNK) Trading Down 3.2%
NewLink Genetics Corp. (NASDAQ:NLNK)’s share price was down 3.2% during trading on Wednesday . The company traded as low as $10.11 and last traded at $10.19, with a volume of 82,043 shares traded. The stock had previously closed at $10.53.
A number of equities analysts have commented on NLNK shares. Stifel Nicolaus reduced their target price on shares of NewLink Genetics Corp. from $63.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, May 10th. Zacks Investment Research raised shares of NewLink Genetics Corp. from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research note on Tuesday, July 26th. Mizuho reduced their price target on shares of NewLink Genetics Corp. from $52.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, May 10th. Cantor Fitzgerald reissued a “buy” rating and issued a $62.00 price target on shares of NewLink Genetics Corp. in a research note on Friday, April 29th. Finally, SunTrust Banks Inc. downgraded shares of NewLink Genetics Corp. from a “buy” rating to a “neutral” rating and reduced their price target for the company from $59.00 to $12.00 in a research note on Tuesday, May 10th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $23.29.
The firm’s market capitalization is $292.59 million. The firm’s 50-day moving average price is $10.94 and its 200 day moving average price is $14.97.
NewLink Genetics Corp. (NASDAQ:NLNK) last announced its quarterly earnings results on Friday, July 29th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by $0.35. On average, equities analysts expect that NewLink Genetics Corp. will post ($3.06) EPS for the current fiscal year.
A hedge fund recently raised its stake in NewLink Genetics Corp. stock. Cornerstone Capital Management Holdings LLC. increased its position in shares of NewLink Genetics Corp. (NASDAQ:NLNK) by 134.1% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 54,775 shares of the company’s stock after buying an additional 31,375 shares during the period. Cornerstone Capital Management Holdings LLC. owned approximately 0.19% of NewLink Genetics Corp. worth $1,993,000 as of its most recent SEC filing.
NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.